Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT05276050
- Status
- Recruiting
Conditions
- Nicotine Addiction
- Schizophrenia
- Smoking Cessation
Eligibility Criteria
- Sex
- ALL
- Age
- 22 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- active F8-coil delivered rTMS — DEVICEMultiple trains of rTMS in a day, for multiple days.
- active H-coil delivered rTMS — DEVICEMultiple trains of rTMS in a day, for multiple days.
Study Details
Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS and/or follow-ups.
Key Dates
- Start date
- Jun 1, 2022
- Status verified
- Jan 2026
- Primary completion
- Jul 28, 2026
- Completion
- Jan 30, 2027
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Study groupParticipants in this group will receive active F8-coil delivered rTMS.
- Active Comparator: Active control groupParticipants in this group will receive active H-coil delivered rTMS.
Primary Outcome Measure
Resting-state functional connectivity (rsFC) from functional magnetic resonance imaging (fMRI) [ Time Frame: 1 month ]
Central Contacts
- Xiaoming Du, PhD443-882-9717
- Victoria Acosta713-486-2740
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | Houston | Texas | 77054 |
Find similar trials in Houston, TX
By condition
By specialty
Related Studies
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaPHASE3 · Recruiting · Gedeon Richter Plc. · Culver City, California
- Ocrelizumab for Psychosis by AutoimmunityPHASE1/PHASE2 · Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- CLOZAPINE Response in Biotype-1PHASE4 · Recruiting · University of Texas Southwestern Medical Center · Hartford, Connecticut